[A22-32] Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2022
Project no.:
A22-32
Commission:
Commission awarded on 28.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in children from ≥ 2 to < 4 years of age with epilepsy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-48 | Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V | Commission completed |
| A16-08 | Brivaracetam - Benefit assessment according to §35a Social Code Book V | Commission completed |